| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| Other Sizes |
| Targets |
(E)-3-Pentenoic acid is an unsaturated carboxylic acid that does not have specific biological receptors as its primary targets. As a short-chain fatty acid, it may be metabolized through beta-oxidation and incorporated into cellular metabolism. The compound's unsaturated bond (C=C) allows for various chemical transformations, including hydrogenation, epoxidation, and polymerization. The compound's carboxylic acid group can participate in esterification and amidation reactions. Its primary applications are as a biochemical assay reagent and synthetic intermediate rather than as a therapeutic agent. The compound's potential use as a flavoring agent relates to its organoleptic properties.
|
|---|---|
| ln Vitro |
(E)-Pent-3-enoic acid is a biochemical reagent that can be utilized in life science research as an organic compound or biological material.
In vitro, (E)-3-pentenoic acid is used as a biochemical assay reagent and synthetic intermediate. It serves as a starting material for various chemical reactions such as esterification, oxidation, and reduction. The compound is used in organic chemistry and biochemical studies. Cellular assays are typically performed on the compounds synthesized from this building block. The compound's unsaturated carboxylic acid structure allows for diverse derivatization, making it valuable for chemical synthesis and biochemical research. Its potential use as a flavoring agent is also noted. |
| ln Vivo |
In vivo data for (E)-3-pentenoic acid is limited, as it is primarily a research reagent and synthetic intermediate. The compound is classified for research use only and is not intended for human or veterinary therapeutic applications. As a short-chain fatty acid, it would be metabolized through beta-oxidation and the citric acid cycle. The compound's potential use as a flavoring agent suggests it may be consumed in small amounts in food products. Specific in vivo data for therapeutic applications is not available in the public literature. The compound is not a therapeutic agent.
|
| Enzyme Assay |
In vitro enzyme assays for (E)-3-pentenoic acid are not typically performed, as it is primarily a chemical reagent and synthetic intermediate. The compound is used as a starting material in chemical reactions rather than as an enzyme inhibitor or activator. A typical assay involves using the compound in organic synthesis reactions, such as esterification with alcohols to form esters or hydrogenation to form saturated acids. The compound is dissolved in organic solvents such as ethanol or dichloromethane. The resulting products can be evaluated for biological activity. The compound's reactivity as an unsaturated acid makes it valuable for chemical synthesis.
|
| Cell Assay |
Cellular assays for (E)-3-pentenoic acid are not standard, as the compound is primarily a chemical reagent. The compound's potential use as a flavoring agent suggests low cytotoxicity at typical concentrations. A typical protocol for evaluating the biological activity of synthesized compounds involves culturing appropriate cell lines in growth medium at 37°C with 5% CO₂. Cells are treated with synthesized compounds at varying concentrations for 24-72 hours. Cell viability, proliferation, or specific signaling readouts are assessed. IC₅₀ or EC₅₀ values are calculated from dose-response curves. The compound itself is not typically tested in cellular assays.
|
| Animal Protocol |
In vivo animal studies for (E)-3-pentenoic acid are not standard, as it is primarily a research reagent. The compound is classified for research use only and is not intended for human or veterinary therapeutic applications. Any animal studies would be limited to toxicological evaluations of the compound as a food additive or flavoring agent. The compound's primary value lies in its use as a synthetic intermediate and research chemical. Specific in vivo protocols are not available in the public literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for (E)-3-pentenoic acid is limited, as it is primarily a research reagent. The compound has a molecular weight of 100.12 g/mol and a molecular formula of C₅H₈O₂. It is a liquid or solid at room temperature. As a short-chain fatty acid, it is expected to be absorbed and metabolized through beta-oxidation. The compound is soluble in organic solvents and has limited water solubility. Specific ADME data is not available. The compound is stored in a dry, cool place.
|
| Toxicity/Toxicokinetics |
(E)-3-Pentenoic acid is classified for research use only and is not intended for human or veterinary applications. Standard safety precautions include handling with appropriate personal protective equipment (gloves, lab coat, safety goggles) in a well-ventilated area. The compound should be stored in a dry, cool place away from incompatible materials. Acute toxicity data is not readily available in the public literature. As with all research chemicals, appropriate laboratory safety practices should be followed. No specific LD₅₀ values or detailed toxicological profiles are available in the public domain.
|
| Additional Infomation |
Pentyl-3-enoic acid is a pentenoic acid with a double bond at the 3-position.
(E)-3-Pentenoic acid ((E)-Pent-3-enoic acid, CAS 1617-32-9) is a biochemical reagent with the molecular formula C₅H₈O₂. It is an unsaturated short-chain carboxylic acid used as a synthetic intermediate, biochemical assay reagent, and potential flavoring agent. The compound is classified as a research-use-only compound not intended for diagnostic or therapeutic purposes. It is available from multiple commercial suppliers in various pack sizes. No clinical trials or approved drug status exist for this compound as it is not a therapeutic agent. Its applications are limited to research and chemical synthesis. |
| Molecular Formula |
C5H8O2
|
|---|---|
| Molecular Weight |
100.12
|
| Exact Mass |
100.052
|
| CAS # |
1617-32-9
|
| PubChem CID |
5282706
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
1.008g/cm3
|
| Boiling Point |
192ºC at 760 mmHg
|
| Flash Point |
89.5ºC
|
| Vapour Pressure |
0.219mmHg at 25°C
|
| Index of Refraction |
1.452
|
| LogP |
1.037
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
7
|
| Complexity |
84.1
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C/C=C/CC(=O)O
|
| InChi Key |
UIUWNILCHFBLEQ-NSCUHMNNSA-N
|
| InChi Code |
InChI=1S/C5H8O2/c1-2-3-4-5(6)7/h2-3H,4H2,1H3,(H,6,7)/b3-2+
|
| Chemical Name |
(E)-pent-3-enoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 9.9880 mL | 49.9401 mL | 99.8801 mL | |
| 5 mM | 1.9976 mL | 9.9880 mL | 19.9760 mL | |
| 10 mM | 0.9988 mL | 4.9940 mL | 9.9880 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
